Librela FAQ

IMPORTANT SAFETY INFORMATION: For use in dogs only. Women who are pregnant, trying to conceive or breastfeeding should take extreme care to avoid self-injection. Hypersensitivity reactions, including anaphylaxis, could potentially occur with self-injection. Librela should not be used in breeding, pregnant or lactating dogs. Librela should not be administered to dogs with known hypersensitivity to bedinvetmab. The most common adverse events reported in a clinical study were urinary tract infections, bacterial skin infections and dermatitis. See full Prescribing Information.

INDICATIONS: For the control of pain associated with osteoarthritis in dogs.

References:

  1. Librela (bedinvetmab injection). Prescribing information. NADA 141-562. Zoetis Inc; March 2023.
  2. Corral, Maria J., et al. “A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis.” Veterinary anaesthesia and analgesia 48.6 (2021): 943-955. https://doi.org/10.1016/j.vaa.2021.08.001.
  3. Michels GM et al. Vet Anaesth Analg. 2023;50(5):446-458. doi:10.1016/j.vaa.2023.06.003.
  4. Anderson KL, Zulch H, O’Neill DG, Meeson RL, Collins LM. Risk factors for canine osteoarthritis and its predisposing arthropathies: a systematic review. Front Vet Sci. 2020;7:200. doi:10.3389/fvets.2020.00220.
  5. IHS Markit. (2021) Canine and Feline Pain Market 2021: Animal Health Market Analysis; Wright A, et al. Identification of canine osteoarthritis using an owner-reported questionnaire and treatment monitoring using functional mobility tests. J Small Anim Pract, 2022. http://doi.org/10.1111/jsap.13500.
  6. PetTrak US Pain Factored National January 2023.
  7. Lascelles BDX, Brown DC, Conzemius MG, Gill M, Oshinsky ML, Sharkey M. Measurement of chronic pain in companion animals: discussions from the Pain in Animals Workshop (PAW) 2017. Vet J. 2019;250:71-78. doi:10.1016/j. tvjl.2019.07.001.
ZPC-02734R2